Michele Park

Michele Park is a Partner on the Healthcare team at NEA based in the US, where she focuses on seed, early, and growth-stage biopharma investments. Prior to joining the venture capital firm in 2021, she served as an investor at Clarus Ventures, a life sciences investment firm that is now part of Blackstone Life Sciences. Earlier in her professional career, Park worked in the financial sector as a biotechnology research analyst for both Credit Suisse and Piper Jaffray. She holds a BA in molecular biology from Princeton University and earned her PhD in molecular biology from the Weill Cornell Graduate School of Medical Sciences, completing her dissertation research at Memorial Sloan Kettering Cancer Center. Park currently leverages her extensive scientific training and capital markets expertise to identify, fund, and scale emerging healthcare enterprises.